Drug Delivery Start-Ups

As an industry segment, drug delivery was virtually created by two companies--Alza Corp. and Elan Corp. PLC. These companies have since evolved into drug companies, abandoning a significant part of the field to second-generation arrivistes. Such companies that have survived the funding drought for small-cap companies have benefited, Inhale Therapeutics, for example, has a number of partnerships for its pulmonary delivery technology. Alkermes, probably the leading drug-delivery pure play, now has its first approved product. What is somewhat surprising about the industry is how little it has consolidated, particularly when one considers that no single drug delivery technology is applicable to a majority of drug delivery problems.

As an industry segment, drug delivery was virtually created by two companies—Alza Corp. and Elan Corp. PLC . And for years, those two companies virtually owned the segment. Anyone with a drug delivery problem, who couldn't solve it alone, naturally went first to Alza or Elan. Technologically competent, financially stable, they were partners of choice.

But with their transformation into drug companies, the role of Alza and Elan as drug delivery technology providers has largely...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial